Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-19
2011-04-19
Aulakh, Charanjit S (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S563000, C514S462000, C514S357000, C514S311000, C514S278000
Reexamination Certificate
active
07928139
ABSTRACT:
Compounds of Formula I and Formula II are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula I and Formula II have the following structures:where the definitions of the variables are provided herein.
REFERENCES:
patent: 3954733 (1976-05-01), Tobiki et al.
patent: 3992371 (1976-11-01), Tobiki et al.
patent: 4215123 (1980-07-01), Scotese et al.
patent: 4374138 (1983-02-01), Haskell et al.
patent: 4382089 (1983-05-01), Haskell et al.
patent: 4404201 (1983-09-01), Haskell et al.
patent: 4468394 (1984-08-01), Machida et al.
patent: 4710473 (1987-12-01), Morris
patent: 5037826 (1991-08-01), Blythin et al.
patent: 5126341 (1992-06-01), Suzuki et al.
patent: 5502035 (1996-03-01), Haviv et al.
patent: 5719164 (1998-02-01), Weidmann et al.
patent: 5798451 (1998-08-01), von Deyn et al.
patent: 5972841 (1999-10-01), von Deyn et al.
patent: 6093730 (2000-07-01), Weidmann et al.
patent: 6593343 (2003-07-01), Björk et al.
patent: 6787326 (2004-09-01), Ratcliffe et al.
patent: 7635715 (2009-12-01), Allen et al.
patent: 2003/0153503 (2003-08-01), Klaus et al.
patent: 2004/0235082 (2004-11-01), Fourney et al.
patent: 2004/0254215 (2004-12-01), Arend et al.
patent: 2005/0020487 (2005-01-01), Klaus et al.
patent: 2005/0107364 (2005-05-01), Hutchinson et al.
patent: 2006/0216295 (2006-09-01), Crabtree et al.
patent: 2006/0251638 (2006-11-01), Guenzler-Pukall et al.
patent: 2006/0276477 (2006-12-01), Klaus et al.
patent: 2007/0004627 (2007-01-01), Seeley et al.
patent: 2007/0203174 (2007-08-01), Klimko et al.
patent: 2007/0249605 (2007-10-01), Allen et al.
patent: 2008/0171756 (2008-07-01), Shaw et al.
patent: 2009/0088475 (2009-04-01), Allen et al.
patent: 2009/0093483 (2009-04-01), Allen et al.
patent: 2009/0099171 (2009-04-01), Allen et al.
patent: 2009/0111806 (2009-04-01), Allen et al.
patent: 2009/0156605 (2009-06-01), Allen et al.
patent: 2009/0156633 (2009-06-01), Allen et al.
patent: 328085 (1976-03-01), None
patent: 0 500 297 (1992-08-01), None
patent: 0 937 459 (1999-08-01), None
patent: 0 547 708 (2003-02-01), None
patent: 1 541 558 (2003-08-01), None
patent: 1 538 160 (2005-06-01), None
patent: 1 449 256 (1976-09-01), None
patent: 493592 (1974-04-01), None
patent: 7224040 (1995-08-01), None
patent: 1735288 (1992-05-01), None
patent: WO 01/85732 (2001-11-01), None
patent: WO 02/076396 (2002-10-01), None
patent: WO 2004/037853 (2004-05-01), None
patent: WO 2004/103974 (2004-12-01), None
patent: WO 2004/104000 (2004-12-01), None
patent: WO 2004/108121 (2004-12-01), None
patent: WO 2004/108681 (2004-12-01), None
patent: WO 2005/011696 (2005-02-01), None
patent: WO 2005/021546 (2005-03-01), None
patent: WO 2005/047285 (2005-05-01), None
patent: WO 2005/077050 (2005-08-01), None
patent: WO 2005/111044 (2005-11-01), None
patent: WO 2006/088246 (2006-08-01), None
patent: WO 2007/038571 (2007-04-01), None
patent: WO 2007/070359 (2007-06-01), None
patent: WO 2007/097929 (2007-08-01), None
patent: WO 2007/103905 (2007-09-01), None
patent: WO 2007/136990 (2007-11-01), None
patent: WO 2007/150011 (2007-12-01), None
patent: WO 2008/040002 (2008-04-01), None
He, L. et al., “Probabilistic Neural Network Multiple Classifier System for Predicting the Genotoxicity of Quinolones and Quinoline Derivatives,” Chem. Res. Toxicol. 18, pp. 428-440 (2005).
Ukrainets, I.V. et al., “4-Hydroxy-2-Quinolines. XXI. 1H-2-Oxo-4-Hydroxyquinoline-3-Carboxylic Alkylamides as a Novel Group of Antihyroid Drugs,” Farmatsevtichnii Zhurnal (Kiev) 6, pp. 54-55 (1995).
Bezuglyi, P.A., “Amides of 4-Hydroxyquinoline-2-oxo-3-carboxylic Acid: Synthesis and Anticoagulant Activity,” Khimiko-Farmatsevticheskii Zhurnal, 24(4) pp. 31-32 (1990).
Schofield, C.J. et al., “Oxygen Sensing by HIF Hydroxylases”, Nature Reviews, Molecular Cell Biology, 5(5), pp. 243-254 (2004).
McDowell, R. S. et al., “From Peptide to Non-Peptide. 2. The De Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold,” J. Am. Chem. Soc. 116(12) pp. 5077-5083 (1994).
Bohnert et al., “Redox Reactions with Cyclopeptide-Like Quinoline Derivatives as Lipophilic, Masked NAD Model Compounds,” Zeitschrift für Naturforschung, B.: Chemical Sciences, 42(9) pp. 1159-1166 (1987).
Kath, J.C. et al., Potent Small Molecule CCR1 Antagonists, Bioorg & Med. Chem. Letters, 14(9), pp. 2169-2173 (2004).
Ukrainets, I.V. et al., “4-Hydroxy-2-Quinolones. 4. Selection of the Optimum Path for Synthesis of N-R-Substituted 4-Hydroxy-2-Quinolone-3-Carboxylic Acid Amides.” Chemistry of Heterocyclic Compounds 28(5), pp. 538-540 (1992).
Warshakoon, N.C. et al., “Design and Synthesis of a Series of Novel Pyrazolopyridines as HIF 1-α Prolyl Hydroxylase Inhibitors,” Bioorg & Med. Chem. Letters, 16, pp. 5687-5690 (2006).
Warshakoon, N.C. et al., “Structure-Based Design, Synthesis, and SAR Evaluation of a New Series of 8-Hydroxyquinolinse as HIF-1α Prolyl Hydroxylase Inhibitors,” Bioorg & Med. Chem. Letters, 16, pp. 5517-5522 (2006).
Warshakoon, N.C. et al., “A Novel Series of Imidazo[1,2-a]pyridine Derivatives as HIF-1α Prolyl Hydroxylase Inhibitors,” Bioorg & Med. Chem. Letters, 16, pp. 5598-5601 (2006).
McDonough, M.A. et al., “Cellular Oxygen Sensing: Crystal Structure of Hypoxia-Inducible Factor Prolyl Hydroxylase (PHD2),” Proc. Natl. Acad. Sci., 103(26) pp. 9814-9819 (2006).
Jöonssen, S. et al., “Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Diorders: Structure-Activity Relationship,” J. Med. Chem. 47, pp. 2075-2088 (2004).
Buckle, D.R. et al., “Synthesis and Antiallergic Activity of 2-Hydroxy-3-nitro-1,4-naphthoquinones,” J. Med. Chem. 20(8), pp. 1059-1064 (1977).
Invitation to Pay Additional Fees and Communication Relating to the Results of the Partial International Search from co-pending PCT Application No. PCT/US2007/025819 mailed on Dec. 19, 2008.
Allen Jennifer R.
Biswas Kaustav
Bryan Marian C.
Burli Roland
Cao Guo-Qiang
Amgen Inc.
Aulakh Charanjit S
Friedrichsen Bernard P.
LandOfFree
Naphthalenone compounds exhibiting prolyl hydroxylase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naphthalenone compounds exhibiting prolyl hydroxylase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naphthalenone compounds exhibiting prolyl hydroxylase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679124